<!DOCTYPE html><html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"><meta name="format-detection" content="telephone=no"><meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no"><link rel="stylesheet" href="css/main.min.css"><script src="js/all.min.js"></script><script type="text/javascript">var slideNumber = 1</script></head><body class="s1"><div class="content-wrap"><nav><div onclick="iRep.go(1)" class="home-button active"></div><ul><li onclick="iRep.go(3)" class="real-world-evidence"><span>REAL WORLD</span></li><li onclick="iRep.go(4)" class="evidence"><span>EVIDENCE</span></li><li onclick="iRep.go(12)" class="reversal"><span>REVERSAL</span></li><li onclick="iRep.go(14)" class="take-action"><span>COST</span></li><li onclick="iRep.goToolbox()" class="toolbox"><span>TOOLBOX</span></li><li onclick="iRep.go(16)" class="pi"><span>PI</span></li></ul></nav><div class="page-nav"><div onclick="iRep.nextSlide()" class="page-next"></div></div><article><div class="bar"><img src="img/s01/text.png"></div><div class="logo"></div><div class="logo2"></div><div class="anticoagulate"><img src="img/s01/anticoagulate.png"></div><div class="green-button"></div><div class="footnote">NOAC: Non-vitamin K antagonist oral anticoagulant.</div><div class="woman"></div><div class="dop">UK/DBG-161129a August 2016</div></article><div class="overlay"></div><div class="sidebar"><ul><li class="indication-tab tab"></li><li class="references-tab tab"></li></ul><div class="panel"><div class="close-button"></div><div class="content indication"><span class="title">Indication<sup>1,2</sup></span><p>Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age<span class="math"> ≥</span>75 years; heart failure (NYHA Class<span class="math"> ≥</span>II); diabetes mellitus; hypertension.</p><p>Pradaxa<sup>®</sup> 110mg b.d. is indicated for patients 80 years and older or taking concomitant verapamil. Pradaxa<sup>®</sup>  110mg b.d. should also be considered if factors present which increase the patient’s bleeding risk.</p><p>Pradaxa<sup>®</sup> 150mg b.d. is indicated for patients under 80 years. In certain situations, a patient taking Pradaxa<sup>®</sup> 150mg b.d. may need to be changed to Pradaxa<sup>®</sup> 110mg b.d., e.g. if their risk of bleeding increases after treatment initiation.</p></div><div class="content references"><div class="text"><b>References: 1.</b> Portola Pharmaceuticals, Inc., Corporate Update, January 2016, available at: http://investors.portola.comlphoenix.zhtml?c=198136&p=iroI-irhome. <br/>Accessed on 03/02/2016.<b> 2.</b> Boehringer Ingelheim. Praxbind<sup>®</sup> Summary of Product Characteristics.<b> 3.</b> Boehringer Ingelheim. Pradaxa<sup>®</sup> 150mg hard capsules Summary <br/> of Product Characteristics.<b> 4.</b> Boehringer Ingelheim. Pradaxa<sup>®</sup> 110mg hard capsules Summary of Product Characteristics.</div></div></div></div></div></body></html>